A recent study reveals that patients who come off new slimming jabs like Mounjaro or Wegovy may regain shed pounds much more quickly than those who end traditional lifestyle regimens.
Research printed in a prominent medical journal points out that while obese individuals can lose substantial amounts of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using these medications should be aware of the risk of fast rebound weight gain when the medication is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery means a return to original weight in about a year and a half.
Weighing Therapies
The analysis, which examined dozens of trials involving thousands of patients, compared the outcomes of these new drugs with other pills.
The team point out that people who shed pounds through lifestyle changes alone usually see a less rapid creep back—perhaps 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Experts suggest the mechanism of the drugs accounts for the amplified weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its endogenous hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in appetite is uncontrolled, making overeating much more probable."
A Lifelong Issue?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals contend that, given the high risk of relapse, the treatment is often ongoing.
This opinion is echoed by drug manufacturers, who say that the findings "emphasize the chronic nature of excess weight," similar to managing conditions like high blood pressure.
User Experiences
People who have come off the medication describe a intense resurgence of hunger.
"It felt as if something flipping and I was suddenly extremely hungry," described one woman.
This challenge is worsened if users have not developed sustainable dietary or behavioural modifications during treatment.
Growing Interest
Figures show that a significant number of people in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and maintained weight loss likely depends on combined lifestyle support.
